Joseph S Zakrzewski
CIK 1331852 · Chief Executive Officer · last filed 2026-03-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.85M
Companies
6
Total Filings
108
Lifetime Open-Market Net
-$51.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANTX | Director | 551,418 | $4.70 | $2.59M | -$1.88M | 12 | 2026-03-23 |
| Cyteir Therapeutics, Inc. (CYT) Delisted | Director | 376,490 | $3.02 | $1.14M | $176.6K | 11 | 2024-02-08 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 60,700 | $0.18 | $10.8K | $147.9K | 9 | 2022-03-01 |
| AMRN | Director | 9,827 | $13.95 | $137.1K | -$45.96M | 38 | 2021-12-16 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | -$2.46M | 15 | 2021-11-22 |
| PODD | Director | 30,558 | $167.47 | $5.12M | -$1.95M | 12 | 2017-05-18 |
Recent Filings · Page 2 of 11
108 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-18 | ANTX | Notice (144) | −100,000 | -$1.91M | EDGAR |
| 2023-06-09 | ANTX | Grant (A) | — | $0 | EDGAR |
| 2023-02-07 | Cyteir Therapeutics, Inc. (CYT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-08 | Cyteir Therapeutics, Inc. (CYT) Delisted | — | — | $0 | EDGAR |
| 2022-12-08 | Cyteir Therapeutics, Inc. (CYT) Delisted | Buy (P) | +21,202 | $27.6K | EDGAR |
| 2022-05-16 | Cyteir Therapeutics, Inc. (CYT) Delisted | Buy (P) | +743 | $1.2K | EDGAR |
| 2022-05-16 | ANTX | Grant (A) | — | $0 | EDGAR |
| 2022-05-12 | Cyteir Therapeutics, Inc. (CYT) Delisted | Buy (P) | +50,406 | $95.1K | EDGAR |
| 2022-03-31 | ANTX | Conv (C) | +98,199 | $0 | EDGAR |
| 2022-03-01 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.